Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo

Abstract

HSP27 form oligomeric structures up to 800 Kda. In cultured cells, the equilibrium between small and large oligomers shifted towards smaller oligomers when phosphorylated on serine residues. To further explore HSP27 structural organization and its repercussion in HSP27 antiapoptotic and tumorigenic properties, we transfected colon cancer REG cells with wild type HSP27 and two mutants in which the phosphorylatable serine residues have been replaced by alanine (to mimic the non phosphorylated protein) or aspartate (to mimic the phosphorylated protein). In growing cells, wild type and alanine mutant formed small and large oligomers and demonstrated antiapoptotic activity while aspartate mutant only formed small multimers and had no antiapoptotic activity. In a cell-free system, only large oligomeric structures interfered with cytochrome c-induced caspase activation, thereby inhibiting apoptosis. The inability of the aspartate mutant to form large oligomers and to protect tumor cells from apoptosis was overcome by growing the cells in vivo, either in syngeneic animals or nude mice. These observations were reproduced by culturing the cells at confluence in vitro. In conclusion (1) large oligomers are the structural organization of HSP27 required for its antiapoptotic activity and (2) cell-cell contacts induce the formation of large oligomers, whatever the status of phosphorylatable serines, thereby increasing cell tumorigenicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Arrigo AP and Welsh WJ. . 1987 J. Biol. Chem. 262: 15359–15369.

  • Arrigo AP, Suhan J and Welsh WJ. . 1988 Mol. Cell. Biol. 8: 5059–5071.

  • Arrigo AP and Landry J. . 1994 The biology of heat shock proteins and molecular chaperons. Morimoto RI, Tissières A and Georgopoulos C (ed). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY pp. 335–373.

  • Arrigo AP. . 1998 Biol. Chem. 379: 19–26.

  • Benndorf R, Hayess K, Ryazantsev S, Wieske M, Behlke J and Lutsch G. . 1994 J. Biol. Chem. 269: 20780–20784.

  • Beresford PJ, Jaju M, Friedman RS, Yoon MJ and Lieberman J. . 1998 J. Immunol. 161: 161–167.

  • Caignard A, Martin MS, Mitchel MS and Martin F. . 1985 Int. J. Cancer 36: 373–377.

  • De Jong WW, Leunissen JA, Leenen PJ, Zweers A and Versteeg M. . 1988 J. Biol. Chem. 263: 5141–5149.

  • Dimanche-Boitrel MT, Pelletier H, Genne P, Petit JM, Le Grimellec C, Ardiet C, Bastian G and Chauffert B. . 1992 Int. J. Cancer 50: 677–682.

  • Ehrnsperger M, Graber S, Gaestel M and Buchner J. . 1997 EMBO J. 16: 221–229.

  • Garrido C, Mehlen P, Fromentin A, Hamman A, Assem M, Arrigo AP and Chauffert B. . 1996 Eur. J. Biochem. 237: 653–659.

  • Garrido C, Ottavi P, Fromentin A, Hamman A, Arrigo AP, Chauffert B and Mehlen P. . 1997 Cancer Res. 57: 2661–2667.

  • Garrido C, Fromentin A, Bonnotte B, Favre N, Moutet M, Arrigo AP, Mehlen P and Solary E. . 1998 Cancer Res. 58: 5495–5499.

  • Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP and Solary E. . 1999 FASEB J. 13: 2061–2070.

  • Hout J, Roy G, Lambert H, Chretien P and Landry J. . 1991 Cancer Res. 51: 5245–5252.

  • Jakob U, Gaestel M, Engels K and Buchner J. . 1993 Biol. Chem. 268: 1517–1520.

  • Kato K, Hasegawa K, Goto S and Inaguma Y. . 1994 J. Biol. Chem. 269: 11274–11278.

  • Konishi H, Matsuzaki H, Tanaka M, Takemura Y, Kuroda S, Ono Y and Kikkawa U. . 1997 FEBS Lett. 410: 493–498.

  • Lambert H, Charette SJ, Bernier AF, Guimond A and Landry J. . 1999 J. Biol. Chem. 274: 9378–9385.

  • Landry J, Chretien P, Lambert H, Hickey E and Weber LA. . 1989 J. Cell. Biol. 109: 7–15.

  • Landry J, Chretien P, Laszlo A and Lambert H. . 1991 J. Cell. Physiol. 147: 93–101.

  • Landry J, Lambert H, Zhou M, Lavoie JN, Hickey E, Weber LA and Anderson CW. . 1992 J. Biol. Chem. 267: 794–803.

  • Lavoie JN, Gingras-Breton G, Tanguay RM and Landry J. . 1993 J. Biol. Chem. 268: 3420–3429.

  • Lavoie JN, Lambert H, Hickey E, Weber LA and Landry J. . 1995 Mol. Cell. Biol. 15: 505–516.

  • Lee GJ, Roseman AM, Saibil HR and Vierling E. . 1997 EMBO J. 16: 659–671.

  • Ludwig S, Engel K, Hoffmeyer A, Sithanandam G, Neufeld B, Palm D, Gaestel M and Rapp UR. . 1996 Mol. Cell. Biol. 16: 6687–6697.

  • Martin F, Caignard A, Jeannin JF, Leclerc A and Martin M. . 1983 Int. J. Cancer 32: 623–628.

  • Mehlen P, Briolay J, Smith L, Diaz-Latoud C, Pauli D and Arrigo AP. . 1993 Eur. J. Biochem. 215: 277–284.

  • Mehlen P and Arrigo AP. . 1994 Eur. J. Biochem. 221: 321–334.

  • Mehlen P, Preville X, Chareyron P, Briolay J, Klemenz R and Arrigo AP. . 1995a J. Immunol. 215: 363–374.

  • Mehlen P, Mehlen A, Guillet D, Preville X and Arrigo AP. . 1995b J. Cell. Biochem. 58: 248–259.

  • Mehlen P, Kretz-Remy C, Briolay J, Fostan P, Mirault ME and Arrigo AP. . 1995c Biochemical J. 312: 367–375.

  • Mehlen P, Schulze-Osthoff K and Arrigo AP. . 1996a J. Biol. Chem. 271: 16510–16514.

  • Mehlen P, Kretz-Remy C, Preville X and Arrigo AP. . 1996b EMBO J. 15: 2695–2706.

  • Mehlen P, Hickey E, Weber LA and Arrigo AP. . 1997 Biochem. Biophys. Res. 241: 187–192.

  • Miron T, Vancompernolle K, Vandekerckhove J, Wilchek M and Geiger B. . 1991 J. Cell. Biol. 114: 255–261.

  • Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P and Martin F. . 1990 Cancer Res. 50: 6626–6631.

  • Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieskel M, Arrigo AP, Buchner J and Gaestel M. . 1999 J. Biol. Chem. 274: 18947–18956.

  • Rösl FA. . 1992 Nucleic Acids Res. 20: 5243–5247.

  • Shimizu T, Martin MS, Pelletier H, Lagadec P and Martin F. . 1989 Immunobiology 178: 401–407.

  • Stokoe D, Engel K, Campbell DG, Cohen P and Gaestel M. . 1992 FEBS Lett. 313: 307–313.

Download references

Acknowledgements

We thank K Nason-Burchenal for her valuable advice. This work was supported by the Institut National pour la Santé et la Recherche Medicale (INSERM), the Comité Departementaux de la Ligue Nationale Contre le Cancer (Cóte d'Or, Nièvre, Saóne et Loire), the Association pour la Recherche Contre le Cancer (# 9567 and 5204), the Conseil Regional de Bougnogne and the Region Rónes-Alpes. JM Bruey was supported by a fellowship from the Ligue Bourguignonne Contre le Cancer.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruey, JM., Paul, C., Fromentin, A. et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 19, 4855–4863 (2000). https://doi.org/10.1038/sj.onc.1203850

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203850

Keywords

This article is cited by

Search

Quick links